Seeking Alpha

Life Technologies Corporation (LIFE)

LIFE is defunct.
  • Jan. 16, 2014, 5:23 PM
    • Tractor Supply (TSCO) will join the S&P 500, replacing Life Technologies (LIFE).
    • TSCO +1.7% AH
    | 1 Comment
  • Jan. 16, 2014, 8:45 AM
    • China's Commerce Ministry has conditionally approved Thermo Fisher Scientific (TMO) $13.6B acquisition of Life Technologies (LIFE).
    • Thermo Fisher will have to reduce the prices of two types of its products it sells in the country, and divest its cell culture and gene adjustment businesses. Thermo Fisher will also have to sell its 51% holding in China's Lanzhou National Hyclone Bio-engineering.
    | Comment!
  • Jan. 6, 2014, 7:24 AM
    • GE Healthcare (GE) has agreed to acquire various businesses from Thermo Fisher (TMO) for $1.06B in a deal that will allow the conglomerate to expand its offering of technologies for cell biology research and cell therapy, and for the manufacture of medicines and vaccines.
    • The operations that GE is buying are Thermo's HyClone cell culture, gene modulation and magnetic beads businesses.
    • Thermo Fisher is selling the operations in order to assuage EU antitrust concerns about the company's acquisition of Life Technologies (LIFE). (PR)
    | Comment!
  • Nov. 26, 2013, 7:14 AM
    • EU competition regulators have approved Thermo Fisher Scientific's (TMO) $13.6B acquisition of of Life Technologies (LIFE) after the U.S. company agreed to sell three subsidiaries to assuage antitrust fears.
    • Themo will sell units that produce and supply media andsera for cell culture, gene silencing products, and polymer-based magnetic beads. (PR)
    | Comment!
  • Nov. 15, 2013, 7:28 AM
    • Thermo Fisher Scientific (TMO) is set to receive a $500M investment from Singapore's sovereign wealth fund Temasek, which will purchase up to 5.28M shares at around $95 each.
    • Thermo will use the money to help pay for its $13.6B acquisition of Life Technologies (LIFE). (8-K)
    | Comment!
  • Nov. 5, 2013, 6:37 PM
    • Life Technologies (LIFE): Q3 EPS of $1.02.
    • Revenue of $936M (+3% Y/Y). (PR)
    | Comment!
  • Sep. 16, 2013, 8:23 AM
    • The FDA grants 501(k) clearance for Quidel's (QDEL) Molecular Influenza A+B assay and Molecular RSV + hMPV assay for use on Life Technologies' (LIFE) QuantStudio" Dx Real-Time PCR Instrument.
    • Notable: The Molecular Influenza A+B assay can detect the H7N9 subtype. (PR)
    • These assays are also cleared for use with Cepheid's (CPHD) SmartCycler II.
    | Comment!
  • Aug. 26, 2013, 10:57 AM
    • Life Technologies (LIFE +0.2%) is partnering with PIKA Weihenstephan - a spin-off from Technical University Munich that develops products and methods for microbiological analysis for breweries - to provide molecular testing applications for the detection of spoilage organisms in the brewing and beverage market.
    • Under the partnership, PIKA Weihenstephan's Fast Orange Nutrient Broth will run on LIFE's real-time PCR instrumentation and will allow brewers to conduct testing in one streamlined workflow solution.
    • This "at-line" testing during processing will help to prevent spoilage and identify potential sources of contamination.
    | Comment!
  • Aug. 5, 2013, 12:22 PM
    • Enzo Biochem (ENZ +8.6%) jumps after a Federal Court Judge upholds the jury verdict issued in November, 2012, which awarded the drug developer $48.6M in damages as a result of patent infringement by Applera Corporation, which is now Life Technologies (LIFE -0.1%).
    • The court ruled initially that LIFE infringed on ENZ's patent covering pioneering technologies relating to compounds used in DNA sequencing systems to read genetic code.
    • The Judge also denied LIFE's request for a finding that Enzo's infringement claims are barred by laches and/or equitable estoppel and its motion for a new trial, as well as ENZ's request for reconsideration seeking additional damages.
    • The ruling opens the way for ENZ to recover prejudgment interest on the damages award, which should exceed $25M in addition to the judgment.
    | Comment!
  • Jul. 31, 2013, 7:01 PM
    • Life Technologies (LIFE): Q2 EPS of $0.98 beats by $0.02.
    • Revenue of $944M misses by $8.06M. (PR)
    | Comment!
  • Jul. 31, 2013, 3:17 PM
    • In a move that "represents a significant step in the growth of [the company] from a research tools provider to a leading medical device company," Life Technologies (LIFE) licenses Dynabeads CD3/CD28 CTS to Novartis (NVS +1.1%).
    • LIFE will supply NVS with proprietary technology for use in immunotherapeutic applications.
    • Specifically, Dynabeads "will be used to isolate, activate and expand T cells" that have been genetically modified to recognize and attack cancer cells. (PR)
    | Comment!
  • Jul. 30, 2013, 8:48 AM
    • Life Technologies (LIFE) has signed a five-year agreement with the FDA to design tests to identify E. coli and Salmonella in food.
    • The FDA will use Life Technologies' Ion PGM Sequencer to generate genome sequence information from defined bacteria, and for strains that will be excluded from detection.
    • The FDA will also call on Life particularly for the development of rapid detection kits. (PR)
    | Comment!
  • Jul. 16, 2013, 8:59 AM
    Life Technologies (LIFE) and Germany's Merk KGaA (MKGAF.PK) join up to work together on a broad range of Life instrument platforms and therapeutic areas. The partnership will initially cover a project for oncology. (PR)
    | Comment!
  • Jun. 26, 2013, 1:31 PM
    Genetic sequencing pioneer Jonathan Rothberg resigns from Life Technologies (LIFE). Mr. Rothberg's resignation - which the company says was expected - comes as the company aims to complete a $13.6B merger with Thermo Fisher Scientific (TMO). The sequencing machine business that Mr. Rothberg ran, Ion Torrent, represents a small percentage of Life's overall revenue, but was cited by Thermo Fisher as oneof the motivating factors behind the acquisition.
    | 1 Comment
  • Jun. 26, 2013, 7:21 AM
    Life Technologies (LIFE) signs a deal granting Suzhou Ribo Life Sciences the exclusive rights to develop siRNA (ribonucleic acid) therapeutics in China using Life's Invivofectamine Rx delivery technology. The first treatment that Suzhou will work on is for Hepatitis B. The Invivofectamine tech uses a proprietary structure to increase the potency by 100-fold and decrease the toxicity of RNAi (interference) compounds. (PR)
    | Comment!
  • Jun. 13, 2013, 8:10 AM
    Life Technologies (LIFE) has bought instrument distributor Life Science Korea (LSK) as part of Life Tech's "go-direct strategy" in South Korea. LSK has been Life Tech's primary instrument distributor since 1994. Financial terms weren't disclosed. (PR)
    | Comment!
Visit Seeking Alpha's
Company Description
Life Technologies Corporation is a global life sciences company dedicated to helping its customers make scientific discoveries and applying those discoveries to ultimately improve the quality of life.
Sector: Healthcare
Industry: Biotechnology
Country: United States